NASDAQ:ERNA 29 October 2025 - 12 May 2026

Ernexa Therapeutics shot higher on Tuesday, though the trading action left plenty of questions. The move was really a textbook biotech squeeze, sparked by fresh investor focus on ERNA-101, their preclinical cell therapy for ovarian cancer. The stock’s thin float and last month’s reverse split set the stage. As of 3:50 p.m. ET, shares were changing hands at $11.43, marking a gain of 58.5%. ERNA swung as high as $15.58, with an intraday floor at $6.86.

Ernexa Therapeutics Inc. – a small Cambridge, MA biotech formerly known as Eterna Therapeutics – saw its stock skyrocket on October 29 after unveiling a major collaboration to advance its cutting-edge cancer therapy. By Wednesday afternoon, ERNA shares were up about 48% as investors piled in on news that Ernexa is partnering with Cellipont Bioservices to scale up ERNA-101 for clinical trialsstocktwits.com. “Shares of Ernexa Therapeutics traded 48% higher on Wednesday afternoon after Cellipont Bioservices announced that it has entered into a collaboration with the company,” Stocktwits reportedstocktwits.com. The stock, which had closed around $1.20 the prior day, surged to roughly $1.80 intraday, marking one of its biggest single-day gains this year.